A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension.
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Iloperidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms REPRIEVE
- Sponsors Novartis; Vanda Pharmaceuticals
- 05 Jul 2016 Results evaluating the safety and effectiveness of iloperidone for the prevention of relapse in schizophrenia published in the CNS Drugs
- 26 May 2016 Primary endpoint (To determine the efficacy of flexible dosing of iloperidone compared with placebo in relapse prevention with evaluation of patients by psychiatric rating scales.) has been met, as reported in a Vanda Pharmaceuticals media release.
- 26 May 2016 Status changed from active, no longer recruiting to discontinued as according to a Vanda Pharmaceuticals media release, in a predefined interim analysis conducted after 68 impending relapse events, confirmed the hypothesis that Fanapt was more effective than placebo in relapse preventions.